Nitrofurantoin-induced acute respiratory distress syndrome during pregnancy: A case report  by Wahba, Sherif S.
Egyptian Journal of Anaesthesia (2014) 30, 101–102Egyptian Society of Anesthesiologists
Egyptian Journal of Anaesthesia
www.elsevier.com/locate/egja
www.sciencedirect.comCase reportNitrofurantoin-induced acute respiratory distress
syndrome during pregnancy: A case report* Tel.: +20 12 111 20212; fax: +20 226330034.
E-mail address: sherifwahba2012@yahoo.com.
Peer review under responsibility of Egyptian Society of Anesthesiol-
ogists.
Production and hosting by Elsevier
1110-1849 ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
http://dx.doi.org/10.1016/j.egja.2013.07.005Sherif S. Wahba *Anesthesia Department, Faculty of Medicine, Ain-Shams University, Abassiya, Cairo, EgyptReceived 26 March 2013; accepted 19 July 2013
Available online 16 August 2013KEYWORDS
Nitrofurantoin;
UTI;
ARDS;
PregnancyAbstract Acute respiratory distress syndrome (ARDS) is a rarely seen complication with nitrfur-
antoin. We report improvement of a parturient who was admitted to our hospital’s obstetrical unit
with life threatening nitrofurantoin-induced acute respiratory failure. She had been taking nitrofu-
rantoin for one week for urinary tract infection (UTI). Her chest radiography showed bilateral
parenchymal inﬁltrates of the lung. The patient responded well to nitrofurantoin discontinuation
and methylprednisolone infusion 1 mg/kg/day.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.Nitrofurantoin-induced pulmonary complications occur in
about 1:100,000 during course of the therapy [1]. These pul-
monary adverse effects were ﬁrst reported in 1962 [2]. In be-
tween 1966 and 1976, 447 cases had been reported from
Sweden and several other reports thereafter [3–6].
1. Case report
A twenty three years old parturient at 33 weeks’ gestation vis-
ited our hospital’s obstetrical clinic complaining of right sided
loin pain. Her routine urine analysis revealed leucocytes, so
nitrofurantoin (a 100 mg capsule, twice per day) was prescribed
for treatment of UTI. One week later, the patient was admittedto our intensive care unit with dyspnea, tachypnea, nonproduc-
tive cough, and low O2 saturation (82%). Her antenatal care
history was unremarkable. Her past medical history was free
from previous history of recurrent miscarriage, thromboembo-
lic disease, or deep venous thrombosis. She denied smoking and
had not recently travelled or exposed to animals before. Her
respiratory rate was 45 breath/min, blood pressure 90/
60 mmHg, hear rate 118 beat/min with regular rhythm, and
temperature 38 C. Chest auscultation revealed only harsh
vesicular breathing, equal air entry with bilateral pulmonary
crackles, and normal heart sounds. Neck veins were not con-
gested, and examination of abdomen and lower limbs was unre-
markable. Initial arterial blood gas analysis revealed
hypocapnea (PaCo2 = 3.3 Kpa) and hypoxaemia
(PaO2 = 7.3 Kpa on O2 mask 6 L/min), so that possibilities
of pulmonary embolism was not excluded. A prophylactic dose
unfractionated heparin (enoxaparin 40 mg s.c) was prescribed
and patient was connected to noninvasive mechanical ventila-
tion (CPAP of 10 cmH2O with FIO2 of 60%) to maintain
SO2P 90%. The patient was monitored by ﬁve-lead ECG,
arterial line, central venous catheter, pulse oximeter, Flowtrac
(Edwards lifesciences vigilio monitor, USA) connected to arte-
102 S.S. Wahbarial line (for measurements of cardiac output, cardiac index,
stoke volume, and systemic vascular resistance), urinary cathe-
ter, and continuous fetal monitoring with cardiotocography
(CTG). Her ECG showed only sinus tachycardia. Lung video
scan showed no probability of pulmonary embolism. Bed-side
transthoracic echocardiography showed no pathological ﬁnd-
ing, LVEF = 50%, pulmonary artery systolic pressure of
20 mmHg and normal Rt. ventricle size. Her chest radiography
showed bilateral parenchymal inﬁltrates of lung. Abdominal
ultrasound was normal. A complete blood count revealed leu-
kocytosis with eosinophilia (WBCs = 14,300/mm3, eosino-
phil = 2860/mm3), normal platelet count (PLT = 156,000/
mm3), and microcytic anemia (Hg = 9.8 gm/dl). Hepatic pro-
ﬁle was within normal range except for high level of lactate
dehydrogenase (256 IU/L). The rest of blood chemistry proﬁle
and cardiac markers were within normal range. Her urine anal-
ysis revealed proteinuria (+2). All cultures and sensitivities for
blood, sputum, urine, and viral studies were negative. Based on
clinical, radiographic and arterial blood gas ﬁndings, the patient
was diagnosed as ARDS. A 48-h after admission, the patient
showed no improvement which necessitates endotracheal intu-
bation and mechanical ventilation using synchronized intermit-
tent mandatory ventilation with low tidal volume (Vt = 6 ml/
kg, RR = 12/min, PEEP = 10 cmH2O, pressure sup-
port = 15 cmH2O and FIO2 = 60%). She was kept sedated
on remifentanil 0.05–0.1 lg/kg/min and propofol = 50 mg/h
infusions. Nitrofurantoin was discontinued and infusion of
methylprednisolone 1 mg/kg/day was started. Enteral feeding
was commenced within 24 h, with conservative ﬂuid manage-
ment strategy, with deep venous thrombosis prophylaxis. On
day 10, her follow-up chest X-ray showed a marked resolution
of previous inﬁltrates with successful weaning and extubation.
Patient was discharged to the ward and delivered after 3 days
a healthy boy by spontaneous vaginal delivery.
2. Discussion
Nitrofurantoin is commonly prescribed for prophylaxis and
treatment of UTI. Nitrofurantoin adverse reactions include
interstitial pulmonary disease, hepatic toxicity as well as periph-
eral neuropathy [7] and few reports described concomitant pul-
monary reactions and hepatic toxicity [8–10]. Despite of the
known pulmonary side effects of nitrofurantoin, this toxicity
is rarely reported in pregnant patients [11]. Nitrofurantoin-in-
duced pulmonary reactions may be presented in there types:
acute, subacute, and chronic. Acute toxicity may develop within
few days [4], subacute type may develop after one month, while
chronic type may appear after 6 months or more. Acute presen-
tation is characterized by fever, cough, dyspnea, rash, cyanosis,
and chest pain [3,7]; meanwhile, chronic presentation is mani-
fested with dyspnea, dry cough, and fatigue, but fever is uncom-
mon [3]. Diagnosis is made by clinical suspension and exclusion
of other causes of respiratory compromise. An increase in bron-
cho-alveolar lavage ﬂuid eosinophils is suggestive of drug in-
duced toxicity. The exact mechanism of acute reactions is still
undetermined [12]. The presence of peripheral blood eosino-
philia in 83% of cases is highly suggestive of hypersensitivity
reaction [1]. Nitrofurantoin-induced hepatotoxicity is postu-
lated to be due a break down product of the drug being com-
bined to an endogenous peptide; this complex is identiﬁed byclass I-HLA antigen [13]. Although our case showed dramatic
improvement after 10 days, prompt improvement within 24 h
had been reported [14]. In fact, management of ARDS is extre-
mely difﬁcult when dealing with two lives: mother and fetus.
CTG allowed safe monitoring of the fetus and sharing decision
with obstetrician, and we decided to continue pregnancy unless
fetal distress was documented. The fundamental strategy in
treatment was drug discontinuation, supportive treatment,
and corticosteroid therapy. In conclusion, although acute pul-
monary reactions to nitrofurantoin are uncommon; life threat-
ening respiratory failure may be encountered. Physician and
obstetrician should be aware of this adverse reaction and its
management.
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